Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
AstraZeneca
Harvard Business School
Boehringer Ingelheim
McKesson

Last Updated: August 15, 2022

XHANCE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Xhance patents expire, and what generic alternatives are available?

Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and seventy-three patent family members in twenty-nine countries.

The generic ingredient in XHANCE is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Xhance

A generic version of XHANCE was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.

  Try it Free

US Patents and Regulatory Information for XHANCE

XHANCE is protected by thirteen US patents.

Patents protecting XHANCE

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Nasal administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Nasal delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Nasal delivery method
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Nasal devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 See Plans and Pricing See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 See Plans and Pricing See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 See Plans and Pricing See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 See Plans and Pricing See Plans and Pricing
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for XHANCE

See the table below for patents covering XHANCE around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3799909 DISPOSITIFS D'ADMINISTRATION NASALE (NASAL DELIVERY DEVICES) See Plans and Pricing
European Patent Office 1180378 Dispositif d'administration nasale (Nasal delivery device) See Plans and Pricing
Mexico 2014010146 DISPOSITIVOS DE SUMINISTRO NASAL. (NASAL DELIVERY DEVICES.) See Plans and Pricing
Russian Federation 2014138493 НАЗАЛЬНОЕ УСТРОЙСТВО ПОДАЧИ ВЕЩЕСТВА See Plans and Pricing
New Zealand 560550 Nasal devices See Plans and Pricing
United Kingdom 2414414 Nasal devices See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XHANCE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2506844 LUC00077 Luxembourg See Plans and Pricing PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1305329 SPC/GB08/026 United Kingdom See Plans and Pricing PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
2506844 18C1022 France See Plans and Pricing PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
1519731 92269 Luxembourg See Plans and Pricing PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
2506844 1890025-8 Sweden See Plans and Pricing PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
2506844 2018C/022 Belgium See Plans and Pricing PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Moodys
Colorcon
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.